Overview

  • Product name

    Myricetin, irreversible TrxR inhibitor
  • Description

    Potent antineoplastic, antioxidant and anti-inflammatory agent
  • Biological description

    Directly inhibits MEK, JAK1, Akt and MKK4 kinase activity. Able to inhibit cytochrome P450 3A4 and 2C9 (IC50 = 7.81 and 13.5 μM, respectively).

  • Purity

    > 97%
  • CAS Number

    529-44-2
  • Chemical structure

    Chemical Structure

Properties

Applications

Our Abpromise guarantee covers the use of ab120721 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Functional Studies Use at an assay dependent concentration.

Images

  • PC 12 cells were incubated at 37°C for 30 minutes with vehicle control (0 µM) and different concentrations of myricetin (ab120721). Increased expression of CaMKII (phospho T286) (ab32678) in PC 12 cells correlates with an increase in myricetin concentration, as described in literature.

    Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 20 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 3% milk before being incubated with ab32678at 1/500 dilution and ab52476 at 1/500 dilution overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.

References

This product has been referenced in:

  • Zou D  et al. Correction: Protective Effects of Myricetin on Acute Hypoxia-Induced Exercise Intolerance and Mitochondrial Impairments in Rats. PLoS One 10:e0133336 (2015). Read more (PubMed: 26176666) »
  • Zou D  et al. Protective effects of myricetin on acute hypoxia-induced exercise intolerance and mitochondrial impairments in rats. PLoS One 10:e0124727 (2015). Read more (PubMed: 25919288) »
  • Li C  et al. Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Eur J Drug Metab Pharmacokinet 36:175-82 (2011). Read more (PubMed: 21442417) »
  • Kang NJ  et al. Myricetin is a potent chemopreventive phytochemical in skin carcinogenesis. Ann N Y Acad Sci 1229:124-32 (2011). Read more (PubMed: 21793847) »
  • Hagenacker T  et al. Myricetin reduces voltage activated potassium channel currents in DRG neurons by a p38 dependent mechanism. Brain Res Bull 83:292-6 (2010). Read more (PubMed: 20655989) »
  • Kumamoto T  et al. Akt is a direct target for myricetin to inhibit cell transformation. Mol Cell Biochem 332:33-41 (2009). Read more (PubMed: 19504174) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab120721.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up